Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| HHSO100201400004I | Other Grant/Funding Number | BARDA | |
| TO# HHSO10033001T | Other Grant/Funding Number | BARDA |
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Rho, Inc. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
The main purpose of this study is to assess the safety and ability of a Panblok H7 influenza vaccine adjuvanted with AS03 or MF59 to generate an immune response after 2 doses separated by 28 days. Three different antigen dose levels of Panblok H7 will be tested.
This is a randomized, double-blinded, phase 2 study to assess safety and immunogenicity of Panblok H7 vaccine at three antigen dose levels (3.75, 7.5, and 15 μg) adjuvanted with AS03 or MF59. The main purpose of this study is to assess the safety and ability of the recombinant Panblok H7 influenza vaccine adjuvanted with AS03 or MF59 to generate an immune response after 2 doses separated by 28 days in healthy males and nonpregnant females, aged 18 to 49 years, inclusive. The expected study duration is approximately 13.5 months per participant.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 3.75 ug Panblok H7 plus AS03 | Experimental | Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 ug Panblok H7 plus AS03 |
|
| 7.5 ug Panblok H7 plus AS03 | Experimental | Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 ug Panblok H7 adjuvanted with AS03 |
|
| 15 ug Panblok H7 plus AS03 | Experimental | Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 ug Panblok H7 adjuvanted with AS03 |
|
| 3.75 ug Panblok H7 plus MF59 | Experimental | Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 ug Panblok H7 adjuvanted with MF59 |
|
| 7.5 ug Panblok H7 plus MF59 | Experimental | Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 ug Panblok H7 adjuvanted with MF59 |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 3.75 ug Panblok H7 | Biological | 0.5 mL recombinant Panblok H7 influenza vaccine antigen 15 ug/mL. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Solicited Local Reactogenicity Symptoms for Participants Given Adjuvant AS03 | Count of participants who experienced at least one of the following during at least one of the time frames specified: Solicited local reactions at the injection site: erythema/redness, induration/swelling, and pain | Day 1-8, Day 29-36 (within 8 days of each vaccination, inclusive of the vaccination day) |
| Solicited Systemic Reactogenicity Symptoms for Participants Given Adjuvant AS03 | Count of participants who experienced at least one of the following during at least one of the time frames specified: Solicited systemic reactions include fever, myalgia (muscle pain), arthralgia (joint pain), fatigue, headache, nausea, vomiting, diarrhea, and chills. | Day 1-8, Day 29-36 (within 8 days of each vaccination, inclusive of the vaccination day) |
| Solicited Local Reactogenicity Symptoms for Participants Given Adjuvant MF59 | Count of participants who experienced at least one of the following during at least one of the time frames specified: Solicited local reactions at the injection site: erythema/redness, induration/swelling, and pain | Day 1-8, Day 29-36 (within 8 days of each vaccination, inclusive of the vaccination day) |
| Solicited Systemic Reactogenicity Symptoms for Participants Given Adjuvant MF59 | Count of participants who experienced at least one of the following during at least one of the time frames specified: Solicited systemic reactions include fever, myalgia (muscle pain), arthralgia (joint pain), fatigue, headache, nausea, vomiting, diarrhea, and chills. | Day 1-8, Day 29-36 (within 8 days of each vaccination, inclusive of the vaccination day) |
| Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant AS03 |
| Measure | Description | Time Frame |
|---|---|---|
| Treatment-emergent Serious Adverse Events (SAEs) for Participants Given Adjuvant AS03 | Count of participants who experienced at least one serious adverse event | Day 1 through Day 394 |
| Treatment-emergent Serious Adverse Events (SAEs) for Participants Given Adjuvant MF59 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Have had a prior severe reaction to any influenza vaccine or have a known allergy to squalene-based adjuvants.
Women who are pregnant or breast feeding. Women of childbearing potential must have a negative urine pregnancy test at screening and within 24 hours prior to each vaccination.
Women of childbearing potential are defined as postmenarcheal and premenopausal females capable of becoming pregnant. This does not include females who meet any of the following conditions: menopausal >12 months, tubal ligation >12 months, bilateral salpingo-oophorectomy, or hysterectomy.
Women of childbearing potential who refuse to use an acceptable method of birth control from screening to Day 50 (Visit 7) or, if sexually active with a male partner, who have not used a reliable birth control method during the 2 months prior to screening.
Adequate contraception is defined as a contraceptive method with a failure rate of less than 1% per year when used consistently and correctly and when applicable, in accordance with the product label, for example: abstinence from penile-vaginal intercourse; oral contraceptives, either combined or progestogen alone; injectable progestogen; implants of etonogestrel or levonorgestrel; estrogenic vaginal ring; percutaneous contraceptive patches; intrauterine device or intrauterine system; male partner sterilization at least 6 months prior to the female participant's Screening Visit, and this male is the sole partner for that participant (the information on the male partner's sterility can come from the site personnel's review of the participant medical records or interview with the participant on her medical history); male condom combined with a vaginal spermicide (foam, gel, film, cream, or suppository); male condom combined with a female diaphragm, either with or without a vaginal spermicide (foam, gel, film, cream, or suppository).
Have immunosuppression as a result of an underlying illness or treatment, or use of anticancer chemotherapy or radiation therapy (cytotoxic) within the preceding 36 months, or plans to receive immunosuppressive therapy/cytotoxic treatment during study participation.
Have an active neoplastic disease or a history of any hematologic malignancy. However, participants with superficial skin cancer who do not require intervention other than local excision are not excluded.
Have long-term use (≥14 consecutive days) of glucocorticoids including oral or parenteral prednisone or prednisone equivalent (>20 mg total dose per day) or high-dose inhaled steroids (>800 µg/day of beclomethasone dipropionate or equivalent) within 1 month prior to screening in this study. However, participants on low-dose inhaled steroids (≤800 µg/day of beclomethasone dipropionate or equivalent) or topical steroids are not excluded.
History of schizophrenia, bipolar disease, psychosis, or severe personality disorder.
History of hospitalization for psychiatric illness, attempted suicide, or having been deemed a danger to self or others within the past 10 years.
Have received immunoglobulin or other blood product (with the exception of Rho[D] immune globulin) within the 3 months prior to screening in this study.
Have received any live vaccines within 4 weeks or inactivated or recombinant protein vaccines within 2 weeks prior to screening in this study or plan to receive such vaccines (including seasonal influenza vaccines) from screening through 21 days following the second dose of the study vaccine (Screening Visit through Day 50).
Have an acute or chronic medical condition that, in the opinion of the site investigator, would render vaccination unsafe or would interfere with the evaluation of responses. This includes all PIMMCs such as Guillain Barré syndrome, narcolepsy, and current or history of autoimmune or chronic inflammatory disease.
Have an acute illness, including body temperature greater than 100.4°F, at screening, immediately prior to each vaccination or, per participant report, within 3 days prior to each vaccination in this study.
Received an experimental agent (vaccine, drug, biologic, device, blood product, or medication) within 1 month prior to screening in this study or expect to receive an experimental agent during the study period.
Are participating or plan to participate in another interventional clinical trial (either active or follow up phase) during the study period.
Participated in an A(H7) influenza vaccine study in the past or have a history of A(H7) influenza infection prior to vaccination in this study.
Have known human immunodeficiency virus, hepatitis B, or hepatitis C infection (based on medical history).
Have a history of alcohol or drug abuse in the last 5 years.
Have a body mass index >35 kg/m2.
Have a first degree relative with narcolepsy.
Have any laboratory test result or clinical findings (including vital signs) that singly or in combination are likely to unfavorably alter the risk-benefit of participation or to confound study safety or immunogenicity results. participants cannot be rescreened based on abnormal laboratory test results.
Alanine aminotransferase (AST) >2 times the upper limit of normal (ULN), or bilirubin >1.5 times the ULN unless isolated Gilbert's syndrome. participants cannot be rescreened based on abnormal laboratory test results.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Mark Adams, MD | Central Kentucky Research | Principal Investigator |
| Matthew Davis, MD | Rochester Clinical Research | Principal Investigator |
| Carlos Fierro, MD | Johnson County Clin-Trials | Principal Investigator |
| Terry Poling, MD | Heartland Research Associates | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Johnson County Clin-Trials | Lenexa | Kansas | 66219 | United States | ||
| Heartland Research Associates, LLC |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | 3.75 µg Panblok H7 Plus AS03 | Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus AS03 |
| FG001 | 7.5 µg Panblok H7 Plus AS03 | Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus AS03 |
| FG002 | 15 µg Panblok H7 Plus AS03 | Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus AS03 |
| FG003 | 3.75 µg Panblok H7 Plus MF59 | Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus MF59 |
| FG004 | 7.5 µg Panblok H7 Plus MF59 | Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus MF59 |
| FG005 | 15 µg Panblok H7 Plus MF59 | Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus MF59 |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | 3.75 µg Panblok H7 Plus AS03 | Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus AS03 |
| BG001 | 7.5 µg Panblok H7 Plus AS03 | Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus AS03 |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Solicited Local Reactogenicity Symptoms for Participants Given Adjuvant AS03 | Count of participants who experienced at least one of the following during at least one of the time frames specified: Solicited local reactions at the injection site: erythema/redness, induration/swelling, and pain | Safety population includes all participants who received any amount of study vaccination. | Posted | Count of Participants | Participants | Day 1-8, Day 29-36 (within 8 days of each vaccination, inclusive of the vaccination day) |
|
13 months
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | 3.75 ug Panblok H7 Plus AS03 | Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 ug Panblok H7 plus AS03 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Cardiac septal defect | Congenital, familial and genetic disorders | MedDRA 20.0 | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Diarrhoea | Gastrointestinal disorders | MedDRA 20.0 | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Silvija Tresnjak-Smith | BARDA | 202-557-1993 | Silvija.Tresnjak-Smith@hhs.gov |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Jul 3, 2017 | Apr 22, 2020 | Prot_002.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Oct 17, 2018 | Apr 22, 2020 | SAP_003.pdf |
Not provided
| ID | Term |
|---|---|
| D007251 | Influenza, Human |
| D005585 | Influenza in Birds |
| D009976 | Orthomyxoviridae Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D012141 | Respiratory Tract Infections |
| D012140 | Respiratory Tract Diseases |
| ID | Term |
|---|---|
| D007239 | Infections |
| D001715 | Bird Diseases |
| D000820 | Animal Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C089950 | MF59 oil emulsion |
Not provided
Not provided
Not provided
Participants will be randomized to one of the six treatment groups at Day 1 and will receive the assigned dose of antigen and adjuvant on Day 1 and Day 29.
Not provided
Not provided
Not provided
| 15 ug Panblok H7 plus MF59 | Experimental | Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 ug Panblok H7 adjuvanted with MF59 |
|
| 7.5 ug Panblok H7 | Biological | Mix 0.5 mL recombinant Panblok H7 influenza vaccine antigen 30 ug/mL. |
|
| 15 ug Panblok H7 | Biological | Mix 0.5 mL recombinant Panblok H7 influenza vaccine antigen 60 ug/mL. |
|
| MF59 | Biological | 0.5 mL MF59 (39 mg squalene/mL ) adjuvant. |
|
| AS03 | Biological | 0.5 mL AS03 (42.4 mg squalene/mL ) adjuvant. |
|
The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer >= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.
| Day 50 |
| Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant MF59 | The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer >= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals. | Day 50 |
| Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant AS03 | The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer >= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals. | Day 50 |
| Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant MF59 | The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer >= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals. | Day 50 |
Count of participants who experienced at least one serious adverse event |
| Day 1 through Day 394 |
| Treatment-emergent Medically Attended Adverse Events (MAAEs) for Participants Given Adjuvant AS03 | Count of participants who experienced at least one adverse event that requires a visit to medical personnel, including hospital, emergency room, urgent care clinic, or other visits to or from medical personnel for any reason occurring post-vaccination. | Day 1 through Day 394 |
| Treatment-emergent Medically Attended Adverse Events (MAAEs) for Participants Given Adjuvant MF59 | Count of participants who experienced at least one adverse event that requires a visit to medical personnel, including hospital, emergency room, urgent care clinic, or other visits to or from medical personnel for any reason occurring post-vaccination. | Day 1 through Day 394 |
| Treatment-emergent Potentially Immune Mediated Medical Conditions (PIMMCs) for Participants Given Adjuvant AS03 | Count of participants who experienced at least one medical condition that was potentially immune mediated occurring post-vaccination | Day 1 through Day 394 |
| Treatment-emergent Potentially Immune Mediated Medical Conditions (PIMMCs) for Participants Given Adjuvant MF59 | Count of participants who experienced at least one medical condition that was potentially immune mediated occurring post-vaccination | Day 1 through Day 394 |
| Treatment-emergent Unsolicited Adverse Events for Participants Given Adjuvant AS03 | Count of participants who experienced at least one unsolicited adverse event (i.e. adverse events not included in the solicited local and systemic adverse event list nor considered a serious AE, MAAE or PIMMC ) that occur post-vaccination. | Day 1 through Day 53, which is the upper window of the Day 50 visit |
| Treatment-emergent Unsolicited Adverse Events for Participants Given Adjuvant MF59 | Count of participants who experienced at least one unsolicited adverse event (i.e. adverse events not included in the solicited local and systemic adverse event list nor considered a serious AE, MAAE or PIMMC) that occur post-vaccination. | Day 1 through Day 50 |
| Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant AS03 | The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer >= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals. | Day 50 |
| Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant MF59 | The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer >= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals. | Day 50 |
| Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant AS03 | The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer >= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals. | Day 50 |
| Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Guangdong Strain for Participants Given Adjuvant AS03 | Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. | Screening and Days 29, 50, 121 and 212 |
| Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant MF59 | The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer >= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals. | Day 50 |
| Seroconversion Based on Serum Microneutralization (MN) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant AS03 | The percentage of participants obtaining seroconversion based on MN antibody titers, defined as either a prevaccination MN titer <1:10 and a postvaccination MN titer ≥1:40, or a prevaccination MN titer ≥1:10 and a minimum 4 fold rise in postvaccination MN titer. Seroconversion represents the minimum intended effect of vaccination. | Days 29, 50, 121, and 212 |
| Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Guangdong Strain for Participants Given Adjuvant MF59 | Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. | Screening and Days 29, 50, 121 and 212 |
| Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Guangdong Strain for Participants Given Adjuvant MF59 | Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. | Day 50 |
| Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant AS03 | Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. | Screening and Days 29, 50, 121 and 212 |
| Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant AS03 | Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. | Day 50 |
| Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant MF59 | Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. | Screening and Days 29, 50, 121 and 212 |
| Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant MF59 | Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. | Day 50 |
| Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant AS03 | The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer >= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals. | Screening, Day 29, Day 121, Day 212 |
| Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant MF59 | The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer >= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals. | Screening, Day 29, Day 121, Day 212 |
| Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Hong Kong Strain for Participants Given Adjuvant AS03 | The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer >= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals. | Screening, Day 29, Day 121, Day 212 |
| Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Hong Kong Strain for Participants Given Adjuvant MF59 | The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer >= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals. | Screening, Day 29, Day 121, Day 212 |
| Seroconversion Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant AS03 | The percentage of participants obtaining seroconversion based on HAI antibody titers, defined as either a prevaccination HAI titer <1:10 and a postvaccination HAI titer ≥1:40, or a prevaccination HAI titer ≥1:10 and a minimum 4 fold rise in postvaccination HAI titer. Seroconversion represents the minimum intended effect of vaccination. | Day 29, Day 50, Day 121, Day 212 |
| Seroconversion Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant MF59 | The percentage of participants obtaining seroconversion based on HAI antibody titers, defined as either a prevaccination HAI titer <1:10 and a postvaccination HAI titer ≥1:40, or a prevaccination HAI titer ≥1:10 and a minimum 4 fold rise in postvaccination HAI titer. Seroconversion represents the minimum intended effect of vaccination. | Day 29, Day 50, Day 121, Day 212 |
| Seroconversion Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Hong Kong Strain for Participants Given Adjuvant AS03 | The percentage of participants obtaining seroconversion based on HAI antibody titers, defined as either a prevaccination HAI titer <1:10 and a postvaccination HAI titer ≥1:40, or a prevaccination HAI titer ≥1:10 and a minimum 4 fold rise in postvaccination HAI titer. Seroconversion represents the minimum intended effect of vaccination. | Day 29, Day 50, Day 121, Day 212 |
| Seroconversion Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Hong Kong Strain for Participants Given Adjuvant MF59 | The percentage of participants obtaining seroconversion based on HAI antibody titers, defined as either a prevaccination HAI titer <1:10 and a postvaccination HAI titer ≥1:40, or a prevaccination HAI titer ≥1:10 and a minimum 4 fold rise in postvaccination HAI titer. Seroconversion represents the minimum intended effect of vaccination. | Day 29, Day 50, Day 121, Day 212 |
| Seroconversion Based on Serum Microneutralization (MN) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant MF59 | The percentage of participants obtaining seroconversion based on MN antibody titers, defined as either a prevaccination MN titer <1:10 and a postvaccination MN titer ≥1:40, or a prevaccination MN titer ≥1:10 and a minimum 4 fold rise in postvaccination MN titer. Seroconversion represents the minimum intended effect of vaccination. | Day 29, Day 50, Day 121, Day 212 |
| Seroconversion Based on Serum Microneutralization (MN) Antibody Titers Against Hong Kong Strain for Participants Given Adjuvant AS03 | The percentage of participants obtaining seroconversion based on MN antibody titers, defined as either a prevaccination MN titer <1:10 and a postvaccination MN titer ≥1:40, or a prevaccination MN titer ≥1:10 and a minimum 4 fold rise in postvaccination MN titer. Seroconversion represents the minimum intended effect of vaccination. | Day 29, Day 50, Day 121, Day 212 |
| Seroconversion Based on Serum Microneutralization (MN) Antibody Titers Against Hong Kong Strain for Participants Given Adjuvant MF59 | The percentage of participants obtaining seroconversion based on MN antibody titers, defined as either a prevaccination MN titer <1:10 and a postvaccination MN titer ≥1:40, or a prevaccination MN titer ≥1:10 and a minimum 4 fold rise in postvaccination MN titer. Seroconversion represents the minimum intended effect of vaccination. | Day 29, Day 50, Day 121, Day 212 |
| Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Guangdong Strain for Participants Given Adjuvant AS03 | Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. | Day 50 |
| Serum Microneutralization (MN) Antibody Titers Against the Guangdong Strain for Participants Given Adjuvant AS03 | Serum MN antibody titers against the H7 antigen (protein) contained in the vaccine. A higher MN titer means a better immune response to the vaccine. | Screening and Days 29, 50, 121 and 212 |
| Serum Microneutralization (MN) Antibody Titers Against the Guangdong Strain for Participants Given Adjuvant MF59 | Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. | Screening and Days 29, 50, 121 and 212 |
| Serum Microneutralization (MN) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant AS03 | Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. | Screening and Days 29, 50, 121 and 212 |
| Serum Microneutralization (MN) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant MF59 | Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. | Screening and Days 29, 50, 121 and 212 |
| Wichita |
| Kansas |
| 67207 |
| United States |
| Central Kentucky Research Associates, Inc. | Lexington | Kentucky | 40509 | United States |
| Rochester Clinical Research, Inc | Rochester | New York | 14609 | United States |
| Withdrawal by Subject |
|
| BARDA regulatory agency or IRB decision |
|
| BG002 | 15 µg Panblok H7 Plus AS03 | Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus AS03 |
| BG003 | 3.75 µg Panblok H7 Plus MF59 | Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus MF59 |
| BG004 | 7.5 µg Panblok H7 Plus MF59 | Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus MF59 |
| BG005 | 15 µg Panblok H7 Plus MF59 | Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus MF59 |
| BG006 | Total | Total of all reporting groups |
| Participants |
|
| Age, Continuous | Mean | Standard Deviation | years |
|
| Sex/Gender, Customized | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus AS03 |
| OG002 | 15 µg Panblok H7 Plus AS03 | Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus AS03 |
|
|
| Primary | Solicited Systemic Reactogenicity Symptoms for Participants Given Adjuvant AS03 | Count of participants who experienced at least one of the following during at least one of the time frames specified: Solicited systemic reactions include fever, myalgia (muscle pain), arthralgia (joint pain), fatigue, headache, nausea, vomiting, diarrhea, and chills. | Safety population includes all participants who received any amount of study vaccination. | Posted | Count of Participants | Participants | Day 1-8, Day 29-36 (within 8 days of each vaccination, inclusive of the vaccination day) |
|
|
|
| Primary | Solicited Local Reactogenicity Symptoms for Participants Given Adjuvant MF59 | Count of participants who experienced at least one of the following during at least one of the time frames specified: Solicited local reactions at the injection site: erythema/redness, induration/swelling, and pain | Safety population includes all participants who received any amount of study vaccination. | Posted | Count of Participants | Participants | Day 1-8, Day 29-36 (within 8 days of each vaccination, inclusive of the vaccination day) |
|
|
|
| Primary | Solicited Systemic Reactogenicity Symptoms for Participants Given Adjuvant MF59 | Count of participants who experienced at least one of the following during at least one of the time frames specified: Solicited systemic reactions include fever, myalgia (muscle pain), arthralgia (joint pain), fatigue, headache, nausea, vomiting, diarrhea, and chills. | Safety population includes all participants who received any amount of study vaccination. | Posted | Count of Participants | Participants | Day 1-8, Day 29-36 (within 8 days of each vaccination, inclusive of the vaccination day) |
|
|
|
| Primary | Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant AS03 | The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer >= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals. | Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments | Posted | Count of Participants | Participants | Day 50 |
|
|
|
| Primary | Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant MF59 | The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer >= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals. | Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments | Posted | Count of Participants | Participants | Day 50 |
|
|
|
| Primary | Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant AS03 | The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer >= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals. | Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments | Posted | Count of Participants | Participants | Day 50 |
|
|
|
| Primary | Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant MF59 | The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer >= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals. | Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments | Posted | Count of Participants | Participants | Day 50 |
|
|
|
| Secondary | Treatment-emergent Serious Adverse Events (SAEs) for Participants Given Adjuvant AS03 | Count of participants who experienced at least one serious adverse event | Safety population includes all participants who received any amount of study vaccination. | Posted | Count of Participants | Participants | Day 1 through Day 394 |
|
|
|
| Secondary | Treatment-emergent Serious Adverse Events (SAEs) for Participants Given Adjuvant MF59 | Count of participants who experienced at least one serious adverse event | Safety population includes all participants who received any amount of study vaccination. | Posted | Count of Participants | Participants | Day 1 through Day 394 |
|
|
|
| Secondary | Treatment-emergent Medically Attended Adverse Events (MAAEs) for Participants Given Adjuvant AS03 | Count of participants who experienced at least one adverse event that requires a visit to medical personnel, including hospital, emergency room, urgent care clinic, or other visits to or from medical personnel for any reason occurring post-vaccination. | Safety population includes all participants who received any amount of study vaccination. | Posted | Count of Participants | Participants | Day 1 through Day 394 |
|
|
|
| Secondary | Treatment-emergent Medically Attended Adverse Events (MAAEs) for Participants Given Adjuvant MF59 | Count of participants who experienced at least one adverse event that requires a visit to medical personnel, including hospital, emergency room, urgent care clinic, or other visits to or from medical personnel for any reason occurring post-vaccination. | Safety population includes all participants who received any amount of study vaccination. | Posted | Count of Participants | Participants | Day 1 through Day 394 |
|
|
|
| Secondary | Treatment-emergent Potentially Immune Mediated Medical Conditions (PIMMCs) for Participants Given Adjuvant AS03 | Count of participants who experienced at least one medical condition that was potentially immune mediated occurring post-vaccination | Safety population includes all participants who received any amount of study vaccination. | Posted | Count of Participants | Participants | Day 1 through Day 394 |
|
|
|
| Secondary | Treatment-emergent Potentially Immune Mediated Medical Conditions (PIMMCs) for Participants Given Adjuvant MF59 | Count of participants who experienced at least one medical condition that was potentially immune mediated occurring post-vaccination | Safety population includes all participants who received any amount of study vaccination. | Posted | Count of Participants | Participants | Day 1 through Day 394 |
|
|
|
| Secondary | Treatment-emergent Unsolicited Adverse Events for Participants Given Adjuvant AS03 | Count of participants who experienced at least one unsolicited adverse event (i.e. adverse events not included in the solicited local and systemic adverse event list nor considered a serious AE, MAAE or PIMMC ) that occur post-vaccination. | Safety population includes all participants who received any amount of study vaccination. | Posted | Count of Participants | Participants | Day 1 through Day 53, which is the upper window of the Day 50 visit |
|
|
|
| Secondary | Treatment-emergent Unsolicited Adverse Events for Participants Given Adjuvant MF59 | Count of participants who experienced at least one unsolicited adverse event (i.e. adverse events not included in the solicited local and systemic adverse event list nor considered a serious AE, MAAE or PIMMC) that occur post-vaccination. | Safety population includes all participants who received any amount of study vaccination. | Posted | Count of Participants | Participants | Day 1 through Day 50 |
|
|
|
| Secondary | Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant AS03 | The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer >= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals. | The immunogenicity full analysis population (IFAP) includes all participants who were randomized, received at least one vaccination, and had determinate assay results at any post-vaccination visit. Only participants with non-missing Day 50 results are included in this analysis. | Posted | Count of Participants | Participants | Day 50 |
|
|
|
| Secondary | Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant MF59 | The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer >= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals. | The immunogenicity full analysis population (IFAP) includes all participants who were randomized, received at least one vaccination, and had determinate assay results at any post-vaccination visit. Only participants with non-missing Day 50 results are included in this analysis. | Posted | Count of Participants | Participants | Day 50 |
|
|
|
| Secondary | Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant AS03 | The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer >= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals. | The immunogenicity full analysis population (IFAP) includes all participants who were randomized, received at least one vaccination, and had determinate assay results at any post-vaccination visit. Only participants with non-missing Day 50 results are included in this analysis. | Posted | Count of Participants | Participants | Day 50 |
|
|
|
| Secondary | Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Guangdong Strain for Participants Given Adjuvant AS03 | Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. | Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments | Posted | Geometric Mean | 95% Confidence Interval | Titers | Screening and Days 29, 50, 121 and 212 |
|
|
|
| Secondary | Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant MF59 | The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer >= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals. | The immunogenicity full analysis population (IFAP) includes all participants who were randomized, received at least one vaccination, and had determinate assay results at any post-vaccination visit. Only participants with non-missing Day 50 results are included in this analysis. | Posted | Count of Participants | Participants | Day 50 |
|
|
|
| Secondary | Seroconversion Based on Serum Microneutralization (MN) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant AS03 | The percentage of participants obtaining seroconversion based on MN antibody titers, defined as either a prevaccination MN titer <1:10 and a postvaccination MN titer ≥1:40, or a prevaccination MN titer ≥1:10 and a minimum 4 fold rise in postvaccination MN titer. Seroconversion represents the minimum intended effect of vaccination. | Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments | Posted | Count of Participants | Participants | Days 29, 50, 121, and 212 |
|
|
|
| Secondary | Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Guangdong Strain for Participants Given Adjuvant MF59 | Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. | Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments | Posted | Geometric Mean | 95% Confidence Interval | Titers | Screening and Days 29, 50, 121 and 212 |
|
|
|
| Secondary | Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Guangdong Strain for Participants Given Adjuvant MF59 | Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. | The immunogenicity full analysis population (IFAP) includes all participants who were randomized, received at least one vaccination, and had determinate assay results at any post-vaccination visit. Only participants with non-missing Day 50 results are included in this analysis. | Posted | Geometric Mean | 95% Confidence Interval | Titers | Day 50 |
|
|
|
| Secondary | Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant AS03 | Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. | Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments | Posted | Geometric Mean | 95% Confidence Interval | Titers | Screening and Days 29, 50, 121 and 212 |
|
|
|
| Secondary | Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant AS03 | Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. | The immunogenicity full analysis population (IFAP) includes all participants who were randomized, received at least one vaccination, and had determinate assay results at any post-vaccination visit. Only participants with non-missing Day 50 results are included in this analysis. | Posted | Geometric Mean | 95% Confidence Interval | Titers | Day 50 |
|
|
|
| Secondary | Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant MF59 | Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. | Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments | Posted | Geometric Mean | 95% Confidence Interval | Titers | Screening and Days 29, 50, 121 and 212 |
|
|
|
| Secondary | Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant MF59 | Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. | The immunogenicity full analysis population (IFAP) includes all participants who were randomized, received at least one vaccination, and had determinate assay results at any post-vaccination visit. Only participants with non-missing Day 50 results are included in this analysis. | Posted | Geometric Mean | 95% Confidence Interval | Titers | Day 50 |
|
|
|
| Secondary | Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant AS03 | The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer >= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals. | Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments | Posted | Count of Participants | Participants | Screening, Day 29, Day 121, Day 212 |
|
|
|
| Secondary | Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant MF59 | The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer >= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals. | Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments | Posted | Count of Participants | Participants | Screening, Day 29, Day 121, Day 212 |
|
|
|
| Secondary | Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Hong Kong Strain for Participants Given Adjuvant AS03 | The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer >= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals. | Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments | Posted | Count of Participants | Participants | Screening, Day 29, Day 121, Day 212 |
|
|
|
| Secondary | Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Hong Kong Strain for Participants Given Adjuvant MF59 | The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer >= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals. | Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments | Posted | Count of Participants | Participants | Screening, Day 29, Day 121, Day 212 |
|
|
|
| Secondary | Seroconversion Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant AS03 | The percentage of participants obtaining seroconversion based on HAI antibody titers, defined as either a prevaccination HAI titer <1:10 and a postvaccination HAI titer ≥1:40, or a prevaccination HAI titer ≥1:10 and a minimum 4 fold rise in postvaccination HAI titer. Seroconversion represents the minimum intended effect of vaccination. | Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments | Posted | Count of Participants | Participants | Day 29, Day 50, Day 121, Day 212 |
|
|
|
| Secondary | Seroconversion Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant MF59 | The percentage of participants obtaining seroconversion based on HAI antibody titers, defined as either a prevaccination HAI titer <1:10 and a postvaccination HAI titer ≥1:40, or a prevaccination HAI titer ≥1:10 and a minimum 4 fold rise in postvaccination HAI titer. Seroconversion represents the minimum intended effect of vaccination. | Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments | Posted | Count of Participants | Participants | Day 29, Day 50, Day 121, Day 212 |
|
|
|
| Secondary | Seroconversion Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Hong Kong Strain for Participants Given Adjuvant AS03 | The percentage of participants obtaining seroconversion based on HAI antibody titers, defined as either a prevaccination HAI titer <1:10 and a postvaccination HAI titer ≥1:40, or a prevaccination HAI titer ≥1:10 and a minimum 4 fold rise in postvaccination HAI titer. Seroconversion represents the minimum intended effect of vaccination. | Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments | Posted | Count of Participants | Participants | Day 29, Day 50, Day 121, Day 212 |
|
|
|
| Secondary | Seroconversion Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Hong Kong Strain for Participants Given Adjuvant MF59 | The percentage of participants obtaining seroconversion based on HAI antibody titers, defined as either a prevaccination HAI titer <1:10 and a postvaccination HAI titer ≥1:40, or a prevaccination HAI titer ≥1:10 and a minimum 4 fold rise in postvaccination HAI titer. Seroconversion represents the minimum intended effect of vaccination. | Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments | Posted | Count of Participants | Participants | Day 29, Day 50, Day 121, Day 212 |
|
|
|
| Secondary | Seroconversion Based on Serum Microneutralization (MN) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant MF59 | The percentage of participants obtaining seroconversion based on MN antibody titers, defined as either a prevaccination MN titer <1:10 and a postvaccination MN titer ≥1:40, or a prevaccination MN titer ≥1:10 and a minimum 4 fold rise in postvaccination MN titer. Seroconversion represents the minimum intended effect of vaccination. | Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments | Posted | Count of Participants | Participants | Day 29, Day 50, Day 121, Day 212 |
|
|
|
| Secondary | Seroconversion Based on Serum Microneutralization (MN) Antibody Titers Against Hong Kong Strain for Participants Given Adjuvant AS03 | The percentage of participants obtaining seroconversion based on MN antibody titers, defined as either a prevaccination MN titer <1:10 and a postvaccination MN titer ≥1:40, or a prevaccination MN titer ≥1:10 and a minimum 4 fold rise in postvaccination MN titer. Seroconversion represents the minimum intended effect of vaccination. | Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments | Posted | Count of Participants | Participants | Day 29, Day 50, Day 121, Day 212 |
|
|
|
| Secondary | Seroconversion Based on Serum Microneutralization (MN) Antibody Titers Against Hong Kong Strain for Participants Given Adjuvant MF59 | The percentage of participants obtaining seroconversion based on MN antibody titers, defined as either a prevaccination MN titer <1:10 and a postvaccination MN titer ≥1:40, or a prevaccination MN titer ≥1:10 and a minimum 4 fold rise in postvaccination MN titer. Seroconversion represents the minimum intended effect of vaccination. | Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments | Posted | Count of Participants | Participants | Day 29, Day 50, Day 121, Day 212 |
|
|
|
| Secondary | Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Guangdong Strain for Participants Given Adjuvant AS03 | Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. | The immunogenicity full analysis population (IFAP) includes all participants who were randomized, received at least one vaccination, and had determinate assay results at any post-vaccination visit. Only participants with non-missing Day 50 results are included in this analysis. | Posted | Geometric Mean | 95% Confidence Interval | Titers | Day 50 |
|
|
|
| Secondary | Serum Microneutralization (MN) Antibody Titers Against the Guangdong Strain for Participants Given Adjuvant AS03 | Serum MN antibody titers against the H7 antigen (protein) contained in the vaccine. A higher MN titer means a better immune response to the vaccine. | Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments | Posted | Geometric Mean | 95% Confidence Interval | Titers | Screening and Days 29, 50, 121 and 212 |
|
|
|
| Secondary | Serum Microneutralization (MN) Antibody Titers Against the Guangdong Strain for Participants Given Adjuvant MF59 | Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. | Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments | Posted | Geometric Mean | 95% Confidence Interval | Titers | Screening and Days 29, 50, 121 and 212 |
|
|
|
| Secondary | Serum Microneutralization (MN) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant AS03 | Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. | Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments | Posted | Geometric Mean | 95% Confidence Interval | Titers | Screening and Days 29, 50, 121 and 212 |
|
|
|
| Secondary | Serum Microneutralization (MN) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant MF59 | Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. | Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments | Posted | Geometric Mean | 95% Confidence Interval | Titers | Screening and Days 29, 50, 121 and 212 |
|
|
|
| 0 |
| 62 |
| 3 |
| 62 |
| 48 |
| 62 |
| EG001 | 7.5 ug Panblok H7 Plus AS03 | Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 ug Panblok H7 adjuvanted with AS03 | 0 | 60 | 1 | 60 | 47 | 60 |
| EG002 | 15 ug Panblok H7 Plus AS03 | Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 ug Panblok H7 adjuvanted with AS03 | 0 | 62 | 3 | 62 | 40 | 62 |
| EG003 | 3.75 ug Panblok H7 Plus MF59 | Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 ug Panblok H7 adjuvanted with MF59 | 0 | 61 | 1 | 61 | 47 | 61 |
| EG004 | 7.5 ug Panblok H7 Plus MF59 | Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 ug Panblok H7 adjuvanted with MF59 | 0 | 60 | 2 | 60 | 40 | 60 |
| EG005 | 15 ug Panblok H7 Plus MF59 | Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 ug Panblok H7 adjuvanted with MF59 | 0 | 61 | 0 | 61 | 42 | 61 |
| Pulmonary artery stenosis congenital | Congenital, familial and genetic disorders | MedDRA 20.0 | Systematic Assessment |
|
| Appendicitis | Infections and infestations | MedDRA 20.0 | Systematic Assessment |
|
| Bronchitis | Infections and infestations | MedDRA 20.0 | Systematic Assessment |
|
| Diverticulitis | Infections and infestations | MedDRA 20.0 | Systematic Assessment |
|
| Meningitis aseptic | Infections and infestations | MedDRA 20.0 | Systematic Assessment |
|
| Arthritis | Musculoskeletal and connective tissue disorders | MedDRA 20.0 | Systematic Assessment |
|
| Intervertebral disc protrusion | Musculoskeletal and connective tissue disorders | MedDRA 20.0 | Systematic Assessment |
|
| Muscular weakness | Musculoskeletal and connective tissue disorders | MedDRA 20.0 | Systematic Assessment |
|
| Malignant melanoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 20.0 | Systematic Assessment |
|
| Colloid brain cyst | Nervous system disorders | MedDRA 20.0 | Systematic Assessment |
|
| Monoplegia | Nervous system disorders | MedDRA 20.0 | Systematic Assessment |
|
| Abortion spontaneous | Pregnancy, puerperium and perinatal conditions | MedDRA 20.0 | Systematic Assessment |
|
| Nephrolithiasis | Renal and urinary disorders | MedDRA 20.0 | Systematic Assessment |
|
| Nausea | Gastrointestinal disorders | MedDRA 20.0 | Systematic Assessment |
|
| Chills | General disorders | MedDRA 20.0 | Systematic Assessment |
|
| Fatigue | General disorders | MedDRA 20.0 | Systematic Assessment |
|
| Injection site erythema | General disorders | MedDRA 20.0 | Systematic Assessment |
|
| Injection site induration | General disorders | MedDRA 20.0 | Systematic Assessment |
|
| Injection site pain | General disorders | MedDRA 20.0 | Systematic Assessment |
|
| Pyrexia | General disorders | MedDRA 20.0 | Systematic Assessment |
|
| Upper respiratory tract infection | Infections and infestations | MedDRA 20.0 | Systematic Assessment |
|
| Blood creatine phosphokinase increased | Investigations | MedDRA 20.0 | Systematic Assessment |
|
| Arthralgia | Musculoskeletal and connective tissue disorders | MedDRA 20.0 | Systematic Assessment |
|
| Myalgia | Musculoskeletal and connective tissue disorders | MedDRA 20.0 | Systematic Assessment |
|
| Headache | Nervous system disorders | MedDRA 20.0 | Systematic Assessment |
|
| Cough | Respiratory, thoracic and mediastinal disorders | MedDRA 20.0 | Systematic Assessment |
|
Not provided
Not provided
|
| Visit 7/Day 50 |
|
| Visit 8/Day 121 |
|
| Visit 9/Day 212 |
|
| Title | Measurements |
|---|---|
|
| Visit 8/Day 121 |
|
| Visit 9/Day 212 |
|
|
| Visit 7/Day 50 |
|
| Visit 8/Day 121 |
|
| Visit 9/Day 212 |
|
|
| Visit 7/Day 50 |
|
| Visit 8/Day 121 |
|
| Visit 9/Day 212 |
|
|
| Visit 7/Day 50 |
|
| Visit 8/Day 121 |
|
| Visit 9/Day 212 |
|
| Title | Measurements |
|---|---|
|
| Visit 8/Day 121 |
|
| Visit 9/Day 212 |
|
| Title | Measurements |
|---|---|
|
| Visit 8/Day 121 |
|
| Visit 9/Day 212 |
|
| Title | Measurements |
|---|---|
|
| Visit 8/Day 121 |
|
| Visit 9/Day 212 |
|
| Title | Measurements |
|---|---|
|
| Visit 8/Day 121 |
|
| Visit 9/Day 212 |
|
| Title | Measurements |
|---|---|
|
| Visit 8/Day 121 |
|
| Visit 9/Day 212 |
|
| Title | Measurements |
|---|---|
|
| Visit 8/Day 121 |
|
| Visit 9/Day 212 |
|
| Title | Measurements |
|---|---|
|
| Visit 8/Day 121 |
|
| Visit 9/Day 212 |
|
| Title | Measurements |
|---|---|
|
| Visit 8/Day 121 |
|
| Visit 9/Day 212 |
|
| Title | Measurements |
|---|---|
|
| Visit 8/Day 121 |
|
| Visit 9/Day 212 |
|
| Title | Measurements |
|---|---|
|
| Visit 8/Day 121 |
|
| Visit 9/Day 212 |
|
| Title | Measurements |
|---|---|
|
| Visit 8/Day 121 |
|
| Visit 9/Day 212 |
|
|
| Visit 7/Day 50 |
|
| Visit 8/Day 121 |
|
| Visit 9/Day 212 |
|
|
| Visit 7/Day 50 |
|
| Visit 8/Day 121 |
|
| Visit 9/Day 212 |
|
|
| Visit 7/Day 50 |
|
| Visit 8/Day 121 |
|
| Visit 9/Day 212 |
|
|
| Visit 7/Day 50 |
|
| Visit 8/Day 121 |
|
| Visit 9/Day 212 |
|